株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界の主要7カ国の季節性インフルエンザワクチン市場:単回接種での予防効果増大による、次世代の4価ワクチンの市場支配

Seasonal Influenza Vaccines Market in Top Seven Countries to 2018 - Next Generation Quadrivalent Vaccines to Dominate the Market by Offering Broader Protection via Single Dose

発行 GBI Research 商品コード 253374
出版日 ページ情報 英文 106 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: GBI Research社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
世界の主要7カ国の季節性インフルエンザワクチン市場:単回接種での予防効果増大による、次世代の4価ワクチンの市場支配 Seasonal Influenza Vaccines Market in Top Seven Countries to 2018 - Next Generation Quadrivalent Vaccines to Dominate the Market by Offering Broader Protection via Single Dose
出版日: 2012年10月26日 ページ情報: 英文 106 Pages
概要

従来よりも安全で効果的なワクチンの開発や、2009年のH1N1インフルエンザの流行時に社会的関心が高まったことなどから、先進国ではインフルエンザワクチンの需要が増加してきました。これらの国々では公衆衛生に対する高い意識、ワクチン接種率の高さ、政府の予防接種への支援拡大などにより、ワクチンメーカーにとって魅力的な市場となっています。人口の高齢化に伴う罹病リスクの高い人々の増加も、予防接種の拡大を促進しています。主要7カ国のインフルエンザワクチン市場は、2011〜2018年に年平均(CAGR)3.9%の速度で成長し、市場規模は2011年の29億米ドルから2018年には38億米ドルにまで拡大すると予想されています。

当レポートでは、世界の上位7カ国(米国・英国・フランス・イタリア・スペイン・ドイツ・日本)のインフルエンザワクチン市場について分析し、全体的な市場構造(接種パターン、促進・抑制要因や動向見通し(今後8年間の予測値)、各国市場の詳細動向や規制環境、開発中のパイプライン製品の情報、主要企業の市場シェアと概要、主な資本取引の動向などを調査・推計して、その結果を概略以下の構成でお届けします。

第1章 目次

第2章 イントロダクション

第3章 市場概要

  • 季節性インフルエンザワクチンの生産サイクル
  • 主要7カ国の季節性インフルエンザ・ワクチン市場
    • ワクチン接種パターン
    • 市場収益総額
  • 市場促進・抑制要因

第4章 各国の市場環境

  • 米国
    • ワクチン接種パターン
    • ワクチンの費用
    • 市場収益総額
  • 米国:市場促進・抑制要因
  • 英国
    • ワクチン接種パターン
    • ワクチンの費用
    • 市場収益総額
  • 英国:市場促進・抑制要因
  • フランス
    • ワクチン接種パターン
    • ワクチンの費用
    • 市場収益総額
  • フランス:市場促進・抑制要因
  • イタリア
    • ワクチン接種パターン
    • ワクチンの費用
    • 市場収益総額
  • イタリア:市場促進・抑制要因
  • スペイン
    • ワクチン接種パターン
    • ワクチンの費用
    • 市場収益総額
  • スペイン:市場促進・抑制要因
  • ドイツ
    • ワクチン接種パターン
    • ワクチンの費用
    • 市場収益総額
  • ドイツ:市場促進・抑制要因
  • 日本
    • ワクチン接種パターン
    • ワクチンの費用
    • 市場収益総額
  • 日本:市場促進・抑制要因

第5章 規制環境

  • 米国におけるワクチンの承認過程と規制
  • EUにおけるワクチンの承認過程と規制
  • 日本におけるワクチンの承認過程と規制

第6章 パイプライン分析

  • サマリー
  • 研究開発パイプライン:フェーズ別
  • 治験中の有望なワクチン
    • Flu Q-QIV
    • Optaflu
    • Fluzone QIV
    • FluBlok
    • Q-LAIV Flu Vac

第7章 競争環境

  • 市場シェア分析
  • 企業のプロファイル
    • Sanofi Pasteur
    • GlaxoSmithKline
    • Novartis Vaccines
    • AstraZeneca

第8章 戦略的な企業統合

  • 概要
    • 取引の種類別内訳
    • 年度別の内訳
  • 主な企業合併・買収(M&A)取引:直近の4年間(全11件)
  • 主なライセンス契約:直近の4年間(全7件)
  • 主なパートナーシップ取引(全8件)

第9章 付録

図表一覧

目次
Product Code: GBIHC265MR

Summary

GBI Research, the leading business intelligence provider, has released its latest research, "Seasonal Influenza Vaccines Market in Top Seven Countries to 2018 - Next Generation Quadrivalent Vaccines to Dominate the Market by Offering Broader Protection via Single Dose", which provides essential insights into seasonal influenza vaccines sales forecasts for the top seven countries, comprising the US, the UK, France, Italy, Spain, Germany and Japan until 2018. It also covers vaccination patterns and geographic distribution and offers a clear view of the regulatory landscape. Additionally, the report includes insights into the seasonal influenza vaccine R&D pipeline and gives profiles of promising vaccines, as well as exploring the competitive landscape through profiles for the top companies. Key trends in terms of M&A and licensing agreements are also analyzed.

GBI Research expects the market to grow at a Compound Annual Growth Rate (CAGR) of 3.9% during the 2011-2018 period from $2.9 billion in 2011 to $3.8 billion by 2018, driven by growing awareness, increasing vaccination coverage and rising government support for immunization against seasonal influenza. On the other hand, limited production capacity, high investment and strict regulations may act as barriers to entry.

The US seasonal influenza vaccine market is the most attractive of those covered in the report in terms of value. It is forecast to increase from $1.6 billion in 2011 to $2.2 billion in 2018 at a CAGR of 4.8%, due to the growth of the aging population, higher disease awareness and the fact that being vaccinated has become more convenient. The UK on the other hand has the most attractive market in terms of growth rate, forecast to grow at CAGR of 6.3% between 2011 and 2018. Germany's market is also attractive and is forecast to grow at a CAGR of 2.7% between 2011 and 2018 from $385.5m to $465m. The market in Japan is forecast to grow at CAGR of 1.6% between 2011 and 2018 to reach $621.5m by 2018, driven by the threat of pandemic influenza and higher awareness of influenza vaccination. The government-run influenza immunization program is also helping to increase vaccination coverage.

GBI Research's analysis shows that the R&D pipeline for seasonal influenza vaccines comprises a high number of vaccines in early-stage development, many of which are new formulations or those that have been developed using the cell culture method. Late-stage vaccines are either quadrivalent vaccines or pediatric versions of those that have already been approved. The market is currently dominated by trivalent vaccines but will witness the launch of quadrivalent vaccines in the near future.

Scope

  • Data and analysis on the seasonal influenza vaccine market in the top seven countries, comprising the US, the UK, France, Italy, Spain, Germany and Japan
  • Market forecasts for seasonal influenza vaccines until 2018
  • Market data on geographical landscape in terms of country, vaccination coverage, public and private contribution to the total number of doses, vaccine price and market size
  • Key drivers and restraints that have had a significant impact on the market
  • Regulatory landscape, including the approval process and an overview of the regulatory authorities in the top seven countries
  • Competitive landscape of the seasonal influenza vaccine market in the top seven countries including top companies' profiles, namely Sanofi, Johnson & Johnson, GlaxoSmithKline Biologicals, Novartis Vaccines and AstraZeneca
  • Key M&A activities and licensing agreements that have taken place between 2009 and mid-2012

Reasons to buy

  • Build effective strategies to launch pipeline products by identifying potential geographies
  • Exploit in-licensing and out-licensing opportunities by identifying products that might fill portfolio gaps
  • Develop key strategic initiatives by studying top competitors' key strategies
  • Develop market-entry and market-expansion strategies by identifying the markets poised for strong growth
  • Reinforce R&D pipelines by identifying new target mechanisms able to produce safer and more efficacious first-in-class vaccines

Executive Summary

'Tis the Season to Be Sniffly - Seasonal Influenza Boosts Vaccines Market

Acute viral respiratory infection influenza, or flu, strikes every winter, and several nations are preparing to tackle this illness through dedicated healthcare schemes, states a new report by healthcare experts GBI Research.

The new report* states that patients normally recover within a week or two from the associated fevers, sore throats, coughs, headaches and fatigue, but vulnerable individuals can develop the more severe disease pneumonia which can cause severe illness and even death. Both cases prove a serious public health problem that creates a huge social and economic burden for national healthcare systems, and affects the wider economy as a result of time taken off work.

However, safe and effective vaccines have been available for decades, and the 2009 H1N1 influenza pandemic increased public awareness of the disease, increasing demand for vaccines throughout the US, the UK, France, Italy, Spain, Germany and Japan. These developed countries offer a high awareness of public health and hygiene, wide vaccination coverage, and rising government support for immunization, presenting an attractive market for vaccine manufacturers. Their growing elderly populations also offer large numbers of high risk individuals, prompting wide scale immunization. GBI Research predicts that the influenza vaccine market will grow in these top seven countries at a Compound Annual Growth Rate (CAGR) of 3.9% during the 2011-2018 period, from $2.9 billion to $3.8 billion.

Governments in these nations have responded positively to the threat posed by pandemic and seasonal influenza outbreaks, often adopting national immunization programs to deal with the challenge of large-scale immunization in a short space of time. Through these programs, governments provide reimbursement of the provision of free treatment, immunizing those at risk of infection, while raising awareness of influenza among the general public. Every year during the influenza season in the UK, France, Italy, Spain and Germany, free doses of seasonal influenza vaccines are supplied to elderly people, pregnant women, chronically ill individuals and other high risk groups, based on the recommendations of the World Health Organization (WHO). In the US, influenza costs are completely reimbursed by Medicaid for the insured population.

The vaccinated population in the top seven countries accounted for 28.9% of the overall population in 2011, with the highest overall vaccination coverage rate (40.9%) seen in the US and the lowest (18.1%) in Italy. The vaccinated population in the top seven countries is forecast to increase to 32.9% in 2018.

Seasonal Influenza Vaccines Market in Top Seven Countries to 2018 - Next Generation Quadrivalent Vaccines to Dominate the Market by Offering Broader Protection via Single Dose

This report provides essential insights into seasonal influenza vaccines sales forecasts for the top seven countries, comprising the US, the UK, France, Italy, Spain, Germany and Japan until 2018. It also covers vaccination patterns and geographic distribution and offers a clear view of the regulatory landscape. Additionally, the report includes insights into the seasonal influenza vaccine R&D pipeline and gives profiles of promising vaccines, as well as exploring the competitive landscape through profiles for the top companies. Key trends in terms of M&A and licensing agreements are additionally analyzed.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Seasonal Influenza Vaccines Market in Top Seven Countries. Introduction

3. Seasonal Influenza Vaccine Market in Top Seven Countries. Market Overview

  • 3.1. Production Cycle for Seasonal Influenza Vaccines
  • 3.2. Seasonal Influenza Vaccine Market in Top Seven Countries
    • 3.2.1. Vaccination Pattern
    • 3.2.2. Total Revenue
  • 3.3. Drivers and Restraints
    • 3.3.1. Drivers
    • 3.3.2. Restraints

4. Seasonal Influenza Vaccine Market in Top Seven Countries. Geographical Landscape

  • 4.1. The US
    • 4.1.1. Vaccination Pattern
    • 4.1.2. Vaccine Cost
    • 4.1.3. Total Revenue
  • 4.2. Drivers and Restraints
    • 4.2.1. Drivers
    • 4.2.2. Barriers
  • 4.3. The UK
    • 4.3.1. Vaccination Pattern
    • 4.3.2. Vaccine Cost
    • 4.3.3. Total Revenue
  • 4.4. Drivers and Restraints
    • 4.4.1. Drivers
    • 4.4.2. Restraint
  • 4.5. France
    • 4.5.1. Vaccination Pattern
    • 4.5.2. Vaccine Cost
    • 4.5.3. Total Revenue
  • 4.6. Drivers and Restraints
    • 4.6.1. Drivers
    • 4.6.2. Restraints
  • 4.7. Italy
    • 4.7.1. Vaccination Pattern
    • 4.7.2. Vaccine Cost
    • 4.7.3. Total Revenue
  • 4.8. Drivers and Restraints
    • 4.8.1. Drivers
    • 4.8.2. Restraints
  • 4.9. Spain
    • 4.9.1. Vaccination Pattern
    • 4.9.2. Vaccine Cost
    • 4.9.3. Total Revenue
  • 4.10. Drivers and Restraints
    • 4.10.1. Drivers
    • 4.10.2. Restraints
  • 4.11. Germany
    • 4.11.1. Vaccination Pattern
    • 4.11.2. Vaccine Cost
    • 4.11.3. Total Revenue
  • 4.12. Drivers and Restraints
    • 4.12.1. Drivers
    • 4.12.2. Restraints
  • 4.13. Japan
    • 4.13.1. Vaccination Pattern
    • 4.13.2. Vaccine Cost
    • 4.13.3. Total Revenue
  • 4.14. Drivers and Restraints
    • 4.14.1. Drivers
    • 4.14.2. Restraints

5. Seasonal Influenza Vaccine Market in Top Seven Countries. Regulatory Landscape

  • 5.1. Registration Process and Regulations for Vaccines in the US
  • 5.2. Registration Process and Regulations for Vaccines in the EU
  • 5.3. Registration Process and Regulations for Vaccines in Japan

6. Seasonal Influenza Vaccine Market in Top Seven Countries. Pipeline Analysis

  • 6.1. Summary
  • 6.2. Research and Development Pipeline by Phase
  • 6.3. Promising Vaccines under Clinical Development
    • 6.3.1. Flu Q-QIV
    • 6.3.2. Optaflu
    • 6.3.3. Fluzone QIV
    • 6.3.4. FluBlok
    • 6.3.5. Q-LAIV Flu Vac

7. Seasonal Influenza Vaccine Market in Top Seven Countries. Competitive Landscape

  • 7.1. Market Share Analysis
  • 7.2. Competitive Profiling
    • 7.2.1. Sanofi Pasteur
    • 7.2.2. GlaxoSmithKline
    • 7.2.3. Novartis Vaccines
    • 7.2.4. AstraZeneca

8. Seasonal Influenza Vaccine Market in Top Seven Countries. Strategic Consolidation

  • 8.1. Overview
    • 8.1.1. Segmentation by Deal Type
    • 8.1.2. Segmentation by Year
  • 8.2. Major Merger and Acquisition Deals, 2009-2012
    • 8.2.1. Intrexon Acquires Neugenesis
    • 8.2.2. Grupo Ferrer Internacional Completes Acquisition of 50% Stake in Alentia Biotech from Laboratorios Farmaceuticos
    • 8.2.3. Nexus Merges with HX Diagnostics
    • 8.2.4. Mymetics Acquires Virosome Biologicals
    • 8.2.5. Abbott Laboratories Acquires Solvay Pharmaceuticals
    • 8.2.6. Nutri Pharma Acquires. Majority Stake in Bionor Immuno
    • 8.2.7. Johnson. Johnson Acquires Crucell
    • 8.2.8. VBI Vaccines Acquires Epixis
    • 8.2.9. Sanofi Pasteur Acquires Remaining 50% Joint Venture Interest in Sanofi Pasteur-Daiichi Sankyo Vaccines
    • 8.2.10. Segmentation by Geography
    • 8.2.11. Segmentation by Year
  • 8.3. Major Licensing Agreements, 2009-2012
    • 8.3.1. Baxter International Expands its Licensing Agreement with Takeda Pharma
    • 8.3.2. AltraVax Enters into Licensing Agreement with Maxygen
    • 8.3.3. iBio Enters into Licensing Agreement with G-Con
    • 8.3.4. NasVax Extends its Research Agreement with Novartis
    • 8.3.5. Protein Sciences Expands its Licensing Agreement with UMN Pharma for FluBlok and PanBlok
    • 8.3.6. Segmentation by Geography
    • 8.3.7. Segmentation by Year
  • 8.4. Major Partnership Deals
    • 8.4.1. Merck Enters into Agreement with CSL Biotherapies
    • 8.4.2. GenVec Enters into an Agreement with SAIC-Frederick
    • 8.4.3. UMN Pharma Enters into Co-Development Agreement with API
    • 8.4.4. Daiichi Sankyo Forms Joint Venture with Kitasato Institute Research
    • 8.4.5. Novartis International Enters into an Agreement with Synthetic Genomics Vaccines
    • 8.4.6. PPD Enters into Collaboration Agreement with Southern Research Institute
    • 8.4.7. Segmentation by Geography
    • 8.4.8. Segmentation by Year

9. Seasonal Influenza Vaccine Market in Top Seven Countries. Appendix

  • 9.1. Market Definitions
  • 9.2. Abbreviations
  • 9.3. Bibliography
  • 9.4. Research Methodology
    • 9.4.1. Secondary Research
    • 9.4.2. Primary Research
    • 9.4.3. Model for Estimation of Seasonal Influenza Vaccine Market
  • 9.5. Geographical Landscape
  • 9.6. Pipeline Analysis
  • 9.7. Competitive Landscape
  • 9.8. Strategic Consolidations
  • 9.9. Contact Us
  • 9.10. Disclaimer

List of Tables

  • Table 1: Seasonal Influenza Vaccine Market, Top Seven Countries, Population ('000), 2011-2018
  • Table 2: Seasonal Influenza Vaccine Market, Top Seven Countries, Vaccination Coverage by Age Group (%), 2011-2018
  • Table 3: Seasonal Influenza Vaccine Market, Top Seven Countries, Overall Vaccination Coverage ('000), 2011-2018
  • Table 4: Seasonal Influenza Vaccine Market, Top Seven Countries, Vaccination Coverage by Age Group ('000), 2011-2018
  • Table 5: Seasonal Influenza Vaccine Market, Top Seven Countries, Total Number of Doses ('000), 2011-2018
  • Table 6: Seasonal Influenza Vaccine Market, Top Seven Countries, Number of Doses by Age Group ('000), 2011-2018
  • Table 7: Seasonal Influenza Vaccine Market, Top Seven Countries, Revenue Forecasts ($m), 2011-2018
  • Table 8: Seasonal Influenza Vaccine Market, The US, Population ('000), 2011-2018
  • Table 9: Seasonal Influenza Vaccine Market, The US, Vaccination Coverage by Age Group (%), 2011-2018
  • Table 10: Seasonal Influenza Vaccine Market, The US, Overall Vaccination Coverage ('000), 2011-2018
  • Table 11: Seasonal Influenza Vaccine Market, The US, Vaccination Coverage by Age Group ('000), 2011-2018
  • Table 12: Seasonal Influenza Vaccine Market, The US, Total Number of Doses ('000), 2011-2018
  • Table 13: Seasonal Influenza Vaccine Market, The US, Number of Doses by Age Group ('000), 2011-2018
  • Table 14: Seasonal Influenza Vaccine Market, The US, Number of Doses by Sector ('000), 2011-2018
  • Table 15: Seasonal Influenza Vaccine Market, The US, Vaccine Cost ($), 2011-2018
  • Table 16: Seasonal Influenza Vaccine Market, The US, Revenue Forecasts ($m), 2011-2018
  • Table 17: Seasonal Influenza Vaccine Market, The UK, Population ('000), 2011-2018
  • Table 18: Seasonal Influenza Vaccine Market, The UK, Vaccination Coverage by Age Group (%), 2011-2018
  • Table 19: Seasonal Influenza Vaccine Market, The UK, Overall Vaccination Coverage ('000), 2011-2018
  • Table 20: Seasonal Influenza Vaccine Market, The UK, Vaccination Coverage by Age Group ('000), 2011-2018
  • Table 21: Seasonal Influenza Vaccine Market, The UK, Total Number of Doses ('000), 2011-2018
  • Table 22: Seasonal Influenza Vaccine Market, The UK, Number of Doses by Age Group ('000), 2011-2018
  • Table 23: Seasonal Influenza Vaccine Market, The UK, Number of Doses by Sector ('000), 2011-2018
  • Table 24: Seasonal Influenza Vaccine Market, The UK, Vaccine Cost ($), 2011-2018
  • Table 25: Seasonal Influenza Vaccine Market, The UK, Revenue Forecasts ($m), 2011-2018
  • Table 26: Seasonal Influenza Vaccine Market, France, Population ('000), 2011-2018
  • Table 27: Seasonal Influenza Vaccine Market, France, Vaccination Coverage by Age Group (%), 2011-2018
  • Table 28: Seasonal Influenza Vaccine Market, France, Overall Vaccination Coverage ('000), 2011-2018
  • Table 29: Seasonal Influenza Vaccine Market, France, Vaccination Coverage by Age Group ('000), 2011-2018
  • Table 30: Seasonal Influenza Vaccine Market, France, Total Number of Doses ('000), 2011-2018
  • Table 31: Seasonal Influenza Vaccine Market, France, Number of Doses by Age Group ('000), 2011-2018
  • Table 32: Seasonal Influenza Vaccine Market, France, Number of Doses by Sector Contribution ('000), 2011-2018
  • Table 33: Seasonal Influenza Vaccine Market, France, Vaccine Cost ($), 2011-2018
  • Table 34: Seasonal Influenza Vaccine Market, France, Revenue Forecasts ($m), 2011-2018
  • Table 35: Seasonal Influenza Vaccine Market, Italy, Population ('000), 2011-2018
  • Table 36: Seasonal Influenza Vaccine Market, Italy, Vaccination Coverage by Age Group (%), 2011-2018
  • Table 37: Seasonal Influenza Vaccine Market, Italy, Overall Vaccination Coverage ('000), 2011-2018
  • Table 38: Seasonal Influenza Vaccine Market, Italy, Vaccination Coverage by Age Group ('000), 2011-2018
  • Table 39: Seasonal Influenza Vaccine Market, Italy, Total Number of Doses ('000), 2011-2018
  • Table 40: Seasonal Influenza Vaccine Market, Italy, Number of Doses by Age Group ('000), 2011-2018
  • Table 41: Seasonal Influenza Vaccine Market, Italy, Number of Doses by Sector Contribution ('000), 2011-2018
  • Table 42: Seasonal Influenza Vaccine Market, Italy, Vaccine Cost ($), 2011-2018
  • Table 43: Seasonal Influenza Vaccine Market, Italy, Revenue Forecasts ($m), 2011-2018
  • Table 44: Seasonal Influenza Vaccine Market, Spain, Population ('000), 2011-2018
  • Table 45: Seasonal Influenza Vaccine Market, Spain, Vaccination Coverage by Age Group (%), 2011-2018
  • Table 46: Seasonal Influenza Vaccine Market, Spain, Overall Vaccination Coverage ('000), 2011-2018
  • Table 47: Seasonal Influenza Vaccine Market, Spain, Vaccination Coverage by Age Group ('000), 2011-2018
  • Table 48: Seasonal Influenza Vaccine Market, Spain, Total Number of Doses ('000), 2011-2018
  • Table 49: Seasonal Influenza Vaccine Market, Spain, Number of Doses by Age Group ('000), 2011-2018
  • Table 50: Seasonal Influenza Vaccine Market, Spain, Number of Doses by Sector Contribution ('000), 2011-2018
  • Table 51: Seasonal Influenza Vaccine Market, Spain, Vaccine Cost ($), 2011-2018
  • Table 52: Seasonal Influenza Vaccine Market, Spain, Revenue Forecasts ($m), 2011-2018
  • Table 53: Seasonal Influenza Vaccine Market, Germany, Population ('000), 2011-2018
  • Table 54: Seasonal Influenza Vaccine Market, Germany, Vaccination Coverage by Age Group (%), 2011-2018
  • Table 55: Seasonal Influenza Vaccine Market, Germany, Overall Vaccination Coverage ('000), 2011-2018
  • Table 56: Seasonal Influenza Vaccine Market, Germany, Vaccination Coverage by Age Group ('000), 2011-2018
  • Table 57: Seasonal Influenza Vaccine Market, Germany, Total Number of Doses ('000), 2011-2018
  • Table 58: Seasonal Influenza Vaccine Market, Germany, Number of Doses by Age Group ('000), 2011-2018
  • Table 59: Seasonal Influenza Vaccine Market, Germany, Number of Doses by Sector ('000), 2011-2018
  • Table 60: Seasonal Influenza Vaccine Market, Germany, Vaccine Cost ($), 2011-2018
  • Table 61: Seasonal Influenza Vaccine Market, Germany, Revenue Forecasts ($m), 2011-2018
  • Table 62: Seasonal Influenza Vaccine Market, Japan, Population ('000), 2011-2018
  • Table 63: Seasonal Influenza Vaccine Market, Japan, Vaccination Coverage by Age Group (%), 2011-2018
  • Table 64: Seasonal Influenza Vaccine Market, Japan, Overall Vaccination Coverage ('000), 2011-2018
  • Table 65: Seasonal Influenza Vaccine Market, Japan, Vaccination Coverage by Age Group ('000), 2011-2018
  • Table 66: Seasonal Influenza Vaccine Market, Japan, Total Number of Doses ('000), 2011-2018
  • Table 67: Seasonal Influenza Vaccine Market, Japan, Number of Doses by Age Group ('000), 2011-2018
  • Table 68: Seasonal Influenza Vaccine Market, Japan, Vaccine Cost ($), 2011-2018
  • Table 69: Seasonal Influenza Vaccine Market, Japan, Revenue Forecasts ($m), 2011-2018
  • Table 70: Seasonal Influenza Vaccine Market, Promising Vaccines by Phase of Development and Company, 2012

List of Figures

  • Figure 1: Seasonal Influenza Vaccine Market, Top Seven Countries, Population ('000), 2011-2018
  • Figure 2: Seasonal Influenza Vaccine Market, Top Seven Countries, Vaccination Coverage by Age Group (%), 2011-2018
  • Figure 3: Seasonal Influenza Vaccine Market, Top Seven Countries, Number of Doses by Age Group ('000), 2011-2018
  • Figure 4: Seasonal Influenza Vaccine Market, Top Seven Countries, Revenue Forecasts ($m), 2011-2018
  • Figure 5: Seasonal Influenza Vaccine Market, Top Seven Countries, Drivers and Restraints
  • Figure 6: Seasonal Influenza Vaccine Market, The US, Population ('000), 2011-2018
  • Figure 7: Seasonal Influenza Vaccine Market, The US, Vaccination Coverage by Age Group (%), 2011-2018
  • Figure 8: Seasonal Influenza Vaccine Market, The US, Number of Doses by Age Group ('000), 2011-2018
  • Figure 9: Seasonal Influenza Vaccine Market, The US, Revenue Forecasts ($m), 2011-2018
  • Figure 10: Seasonal Influenza Vaccine Market, The US, Drivers and Restraints
  • Figure 11: Seasonal Influenza Vaccine Market, The UK, Population ('000), 2011-2018
  • Figure 12: Seasonal Influenza Vaccine Market, The UK, Vaccinated Coverage by Age Group (%), 2011-2018
  • Figure 13: Seasonal Influenza Vaccine Market, The UK, Number of Doses by Age Group ('000), 2011-2018
  • Figure 14: Seasonal Influenza Vaccine Market, The UK, Revenue Forecasts ($m), 2011-2018
  • Figure 15: Seasonal Influenza Vaccine Market, The UK, Drivers and Restraints
  • Figure 16: Seasonal Influenza Vaccine Market, France, Population ('000), 2011-2018
  • Figure 17: Seasonal Influenza Vaccine Market, France, Vaccination Coverage by Age Group (%), 2011-2018
  • Figure 18: Seasonal Influenza Vaccine Market, France, Number of Doses by Age Group ('000), 2011-2018
  • Figure 19: Seasonal Influenza Vaccine Market, France, Revenue Forecasts ($m), 2011-2018
  • Figure 20: Seasonal Influenza Vaccine Market, France, Drivers and Restraints
  • Figure 21: Seasonal Influenza Vaccine Market, Italy, Population ('000), 2011-2018
  • Figure 22: Seasonal Influenza Vaccine Market, Italy, Vaccination Coverage by Age Group (%), 2011-2018
  • Figure 23: Seasonal Influenza Vaccine Market, Italy, Number of Doses by Age Group ('000), 2011-2018
  • Figure 24: Seasonal Influenza Vaccine Market, Italy, Revenue Forecasts ($m), 2011-2018
  • Figure 25: Seasonal Influenza Vaccine Market, Italy, Drivers and Restraints
  • Figure 26: Seasonal Influenza Vaccine Market, Spain, Population ('000), 2011-2018
  • Figure 27: Seasonal Influenza Vaccine Market, Spain, Vaccination Coverage by Age Group (%), 2011-2018
  • Figure 28: Seasonal Influenza Vaccine Market, Spain, Number of Doses by Age Group ('000), 2011-2018
  • Figure 29: Seasonal Influenza Vaccine Market, Spain, Revenue Forecasts ($m), 2011-2018
  • Figure 30: Seasonal Influenza Vaccine Market, Spain, Drivers and Restraints
  • Figure 31: Seasonal Influenza Vaccine Market, Germany, Population ('000), 2011-2018
  • Figure 32: Seasonal Influenza Vaccine Market, Germany, Vaccination Coverage by Age Group (%), 2011-2018
  • Figure 33: Seasonal Influenza Vaccine Market, Germany, Number of Doses by Age Group ('000), 2011-2018
  • Figure 34: Seasonal Influenza Vaccine Market, Germany, Revenue Forecasts ($m), 2011-2018
  • Figure 35: Seasonal Influenza Vaccine Market, Germany, Drivers and Restraints
  • Figure 36: Seasonal Influenza Vaccine Market, Japan, Population ('000), 2011-2018
  • Figure 37: Seasonal Influenza Vaccine Market, Japan, Vaccination Coverage by Age Group (%), 2011-2018
  • Figure 38: Seasonal Influenza Vaccine Market, Japan, Number of Doses by Age Group ('000), 2011-2018
  • Figure 39: Seasonal Influenza Vaccine Market, Japan, Revenue Forecasts ($m), 2011-2018
  • Figure 40: Seasonal Influenza Vaccine Market, Japan, Drivers and Restraints
  • Figure 41: Seasonal Influenza Vaccine Market, Regulatory Authorities, The US, 2012
  • Figure 42: Seasonal Influenza Vaccine Market, Drug Approval Process, The US, 2012
  • Figure 43: Seasonal Influenza Vaccine Market, Regulatory Authorities, EU, 2012
  • Figure 44: Seasonal Influenza Vaccine Market, Approval Process, EU, 2012
  • Figure 45: Seasonal Influenza Vaccine Market, Regulatory Authorities, Japan, 2012
  • Figure 46: Seasonal Influenza Vaccine Market, Drug Approval Process, Japan, 2012
  • Figure 47: Seasonal Influenza Vaccine Market, Top Seven Countries, R&D Pipeline by Phase (%), 2012
  • Figure 48: Seasonal Influenza Vaccine Market, Top Seven Countries, Market Share (%), 2011
  • Figure 49: Seasonal Influenza Vaccine Market, Top Seven Countries, Sanofi, SWOT Analysis
  • Figure 50: Seasonal Influenza Vaccine Market, Top Seven Countries, GSK, SWOT Analysis
  • Figure 51: Seasonal Influenza Vaccine Market, Top Seven Countries, Novartis, SWOT Analysis
  • Figure 52: Seasonal Influenza Vaccine Market, Top Seven Countries, AstraZeneca, SWOT Analysis
  • Figure 53: Seasonal Influenza Vaccine Market, Top Seven Countries, Deals by Type, 2009-2012
  • Figure 54: Seasonal Influenza Vaccine Market, Top Seven Countries, Number of Deals by Year, 2009-2012
  • Figure 55: Seasonal Influenza Vaccine Market, Top Seven Countries, M&A Deals by Geography, 2009-2012
  • Figure 56: Seasonal Influenza Vaccine Market, Top Seven Countries, M&A Deals by Year, 2009-2012
  • Figure 57: Seasonal Influenza Vaccine Market, Top Seven Countries, Licensing Agreements by Geography, 2009-2012
  • Figure 58: Seasonal Influenza Vaccine Market, Top Seven Countries, Number of Licensing Agreements by Year, 2009-2012
  • Figure 59: Seasonal Influenza Vaccine Market, Top Seven Countries, Partnership Deals by Geography, 2009-2012
  • Figure 60: Seasonal Influenza Vaccine Market, Top Seven Countries, Number of Partnership Deals by Year, 2009-2012
  • Figure 61: GBI Research Market Forecasting Model, Estimation of Market for a Country, 2010
Back to Top